- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02621866
A Trial of Daily Ultraviolet Therapy to Reduce Cardiovascular Risk Factors
The investigators have shown that a single dose of ultraviolet irradiation (as found in sunlight) will lower blood pressure for around one hour. They are now testing whether daily UVA for two weeks will produce a sustained fall in BP in patients with high blood pressure.
They will also measure the effect of daily UVA on other cardiovascular risk factors.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Epidemiological studies suggest that sunlight reduces all cause mortality, and particularly cardiovascular mortality.
The investigators have previously shown vasodilatation and a transient fall in blood pressure following irradiation of human volunteers with 2 standard erythemal doses of UVA radiation. This was independent of vitamin D and temperature rise and correlated with a nitric oxide synthase independent mobilisation of NO stores from the skin to the systemic circulation.
In this randomised, sham-controlled, cross-over double blind study, they will measure whether twice daily UVA administration can produce a sustained fall in BP and other cardiovascular risk factors in a cohort of pre-hypertensive patients.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Edinburgh, United Kingdom, EH4 2XU
- Clinical Research Centre and Pharmacology Unit, Western General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pre-hypertensives (BP 120-139/80-89).
- Fitzpatrick skin types 2 and above (i.e. the ability to tan)
Exclusion Criteria:
- History of skin cancer.
- Fitzpatrick type 1 skin (always burns, never tans).
- Red hair.
- Family history of melanoma in first degree relative.
- Atypical naevus syndrome.
- Planned holiday or foreign travel during and for 4 weeks before the period of the study.
Concurrent administration of:
- anti-hypertensive medication,
- photosensitising medication,
- systemic immunosuppressive medication.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Active
UVA irradiation.
|
Twice daily with 10 Joules/cm2.
Half body (one side) with Waldmann 100L phototherapy lamp fitted with UVA bulbs (main emission 320-410nm)
Other Names:
|
SHAM_COMPARATOR: Sham UVA irradiation
|
As active, but lamps to be shielded with Amber 81 museum film which prevents transmission of <500nm, but permits visible light to pass.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
24 hour ambulatory blood pressure measurement
Time Frame: Two weeks
|
Before and after active and sham intervention period.
Subjects will wear a 24 hour ambulatory blood pressure monitor for the 24 hour period before and after each 2 week intervention period.
Change in 24 hour ambulatory blood pressure measurement will be the outcome measure.
|
Two weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood pressure
Time Frame: Two weeks
|
Measured with a mercury sphygmomanometer in clinical research facility.
Change in blood pressure between the before and after measurements in the active and sham intervention.
|
Two weeks
|
Heart rate
Time Frame: Two weeks
|
Change in heart rate between the before and after measurements of the active and sham intervention.
This will be measured manually in clinical research facility before and after active or sham intervention period.
|
Two weeks
|
Body Mass Index
Time Frame: Two weeks
|
Change in body mass index measured in clinical research facility before and after active and sham intervention period
|
Two weeks
|
Waist-Hip Ratio
Time Frame: Two weeks
|
Change in waist-hip ratio.
Measured in clinical research facility before and after active or sham intervention period
|
Two weeks
|
Lipid profile
Time Frame: Two weeks
|
Change in lipid profile.
Blood will be taken in the clinical research facility before and after active and sham intervention period.
Analysis will be performed by the core specialist assay service at the adjacent Queens Medical Research Institute of the University of Edinburgh.
Lipids are measured as a continuous variable.
|
Two weeks
|
Adipokine profile
Time Frame: Two weeks
|
Change in adipokine profile.
Blood will be taken in the clinical research facility before and after active and sham intervention period.
Analysis will be performed by the core specialist assay service at the adjacent Queens Medical Research Institute of the University of Edinburgh.
Adipokines are measured as a continuous variable.
|
Two weeks
|
Glucose tolerance test
Time Frame: Two weeks
|
The standard National Health Service Lothian Glucose Tolerance Test protocol will be carried out and changes in outcome measures recorded. These will be the fasting glucose and the two hour glucose level. Both are continuous variables. Phlebotomy and glucose administration wil be performed in the clinical research facility before and after active and sham intervention period |
Two weeks
|
HbA1c (glycosylated haemoglobin)
Time Frame: Two weeks
|
Change in glycosylated haemoglobin level.
Blood will be taken in the clinical research facility before and after active and sham intervention period.
Analysis will be performed by the core specialist assay service at the adjacent Queens Medical Research Institute of the University of Edinburgh.
Glycosylated haemoglobin is measured as a continuous variable.
|
Two weeks
|
Fasting insulin level
Time Frame: Two weeks
|
Change in fasting insulin level.
Fasting blood will be taken in the clinical research facility before and after active and sham intervention period.
Analysis will be performed by the core specialist assay service at the adjacent Queens Medical Research Institute of the University of Edinburgh.
Insulin levels are measured as a continuous variable.
|
Two weeks
|
Bio-impedance for body fat
Time Frame: Two weeks
|
Changes in body fat levels.
These are measured in clinical research facility before and after active or sham intervention period.
This is a continuous variable.
|
Two weeks
|
Serum Vitamin D level
Time Frame: Two weeks
|
Changes in serum Vitamin D level.
This is a continuous variable.
Blood will be taken in the clinical research facility before and after active or sham intervention period.
Analysis will be performed by the core specialist assay service at the adjacent Queens Medical Research Institute of the University of Edinburgh.
|
Two weeks
|
Adaptive pigmentation
Time Frame: Two weeks
|
Changes in pigmentation.
Measured in clinical research facility before and after active or sham intervention period.
Colour will be measured on UV exposed back skin using a chromameter and the L*a*b*score.
This is a continuous variable.
|
Two weeks
|
Mood
Time Frame: Two weeks
|
Changes in mood.
Patients will complete a mood questionnaire in the clinical research facility at the appointment before and after the active or sham intervention period.
This is a continuous variable.
|
Two weeks
|
Physical activity level- composite measure.
Time Frame: Two weeks
|
Differences in activity levels will be compared between active, sham and washout periods.
A composite measure derived from the peak, mean, and overall activity will be recorded.
Overall activity will be calculated as area under the curve over the measurement period.
Activity will be measured as movement, recorded by continually worn actiwatches (movement monitors) throughout the duration of the study.
These will be set to record movement in 1 minute epochs.
|
Two weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Richard B Weller, MD FRCP, University of Edinburgh
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PG/15/23/31362
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
BayerCompletedPrimary HypertensionChina
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on Ultraviolet A radiation
-
Wright State UniversityRecruiting
-
Bispebjerg HospitalSygehus LillebaeltActive, not recruitingDNA Damage | Ultraviolet Rays; Injury | DNA Adduct Formation | DNA Damage, Radiation InducedDenmark
-
Henry Ford Health SystemTerminatedGeneralized VitiligoUnited States
-
National Center for Research Resources (NCRR)Louisiana State University Health Sciences Center in New OrleansUnknownSystemic Lupus ErythematosusUnited States
-
Mashhad University of Medical SciencesCompleted
-
Nicolas HunzelmannUniversity Hospital TuebingenTerminatedSystemic Sclerosis | Systemic SclerodermaGermany
-
Mayo ClinicTerminatedPsoriasis | DermatitisUnited States
-
Toronto Rehabilitation InstituteOntario Neurotrauma FoundationCompleted
-
Cairo UniversityNot yet recruiting
-
Avita MedicalTerminated